Noven Announces Availability of Clinical Data On Transdermal Combination Hormone Therapy

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the availability of clinical data examining the effects of transdermal combination hormone replacement therapy (HRT) on the sexual quality of life of postmenopausal women and on renin substrate levels, which may impact blood pressure.

Separate posters entitled "CombiPatch® Significantly Improves Women's Sexual Quality of Life Compared to Prempro™ in a Randomized Trial" and "Renin Substrate Levels Decrease With Transdermal Hormone Therapy and Increase With Oral Hormone Therapy" were recently presented at a national medical conference. The data was presented by James A. Simon M.D., of George Washington University; Rebecca G. Rogers, M.D., of the University of New Mexico; and Vanaja V. Rgavan M.D., of Novartis Pharmaceuticals Corporation. Copies of the poster presentations are available at www.noven.com under "Research – Scientific Publications".

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, including the only combination HRT patch available in the United States. For additional information on Noven, visit www.noven.com. Prempro™ is a registered trademark of Wyeth Pharmaceuticals; CombiPatch® is a registered trademark of Novogyne Pharmaceuticals.

Contact:
Investor & Media Contact

Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
305-253-1916